Clinical trial
Study of ATN-224 in Patients With Prostate Cancer
NCT00405574 · Attenuon, Industry · Unknown status
Key facts
| NCT number | NCT00405574 |
|---|---|
| Title | Study of ATN-224 in Patients With Prostate Cancer |
| Official title | A Randomized, Phase II Study of Two Dose Levels of ATN-224 in Patients With Biochemically Relapsed, Early Stage Prostate Cancer Not on Hormone Therapy |
| Lead sponsor | Attenuon, Industry |
| Collaborators | Prostate Cancer Clinical Trials Consortium |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | ATN-224 |
| Enrollment | 50 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Nov 30, 2006 |
| Last update posted | Jan 30, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: